Aziyo Biologics, Inc. AZYO
Sep 6, 2023, 3:59 PM EDT
52-week range unavailable
- Market cap
- 40.59M
- Revenue (ttm)
- 50.74M
- Profit margin
- -64.49%
- Shares out
- 11.92M
- Forward P/E
- -2.84
- Volume
- 8.10K
- Open
- 1.45
- Previous close
- 1.49
- Day's range
- 1.40 – 1.54
- Beta
- -0.17
- Analysts
- Buy
- Price target
- 12.50 (+738.9%)
- Earnings date
- Aug 14, 2023
Key statistics
- Enterprise value
- 52.38M
- PEG ratio
- 0.00
- Price / sales
- 0.80
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.50%
- Free cash flow
- 2.87M
- Total cash
- 11.79M
- Total debt
- 26.01M
- Return on equity
- 0.00%
- Short % of float
- 2.16%
- 50-day average
- 2.31
- 200-day average
- 4.11
Analyst view
Consensus: buy
- Target (low)
- 12.00
- Target (mean)
- 12.50
- Target (high)
- 13.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate -0.35.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 22, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.66 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.55 | — | — | — |
| May 9, 2022 | Mar 1, 2022 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 16, 2022 | Truist Securities | main | — | Buy |
| Nov 15, 2022 | Piper Sandler | main | — | Overweight |
| Mar 4, 2022 | Cowen & Co. | main | — | Outperform |
| Nov 2, 2020 | Truist Securities | init | — | Buy |
| Nov 2, 2020 | Cowen & Co. | init | — | Outperform |
About Aziyo Biologics, Inc.
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women's health, orthobiologics, cardiovascular, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- aziyo.com
News
Elutia to Present at the H.C. Wainwright 25th Annual Global Investment Conference 
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures 
Aziyo Biologics, Inc. (AZYO) Q2 2023 Earnings Call Transcript 
Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company 
Earnings Scheduled For August 14, 2023 
Aziyo Biologics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 
Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products 
Aziyo Biologics, Inc. (AZYO) Q1 2023 Earnings Call Transcript 
Hyatt Hotels To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Friday 
Earnings Scheduled For May 10, 2023
Your note
Sign in to keep a note on AZYO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRCHVIEW CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 26, 2023 | 0 |
| COLPMAN DAVID | Director | Purchase | Dec 14, 2022 | 3,098 |
| EDWARDS PETER G | General Counsel | Conversion of Exercise of derivative security | Sep 7, 2022 | 3,498 |
| ENGLESE THOMAS | Officer | Sale | Mar 8, 2023 | 17,917 |
| FERGUSON MATTHEW B | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 7, 2023 | 46,504 |
| HIGHCAPE CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 4, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Birchview Capital, LP | 13.88% | 1,655,184 | 4.14M | Mar 30, 2023 |
| Perkins Capital Management, Inc. | 2.31% | 275,329 | 688.32K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 2.08% | 248,492 | 621.23K | Mar 30, 2023 |
| Alyeska Investment Group, L.p. | 1.80% | 214,343 | 535.86K | Mar 30, 2023 |
| Prosight Management, LP | 1.65% | 196,443 | 491.11K | Mar 30, 2023 |
| Brown Advisory Inc. | 0.28% | 32,887 | 82.22K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.65% | 195,766 | 489.42K | Dec 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 24,900 | 62.25K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.09% | 11,215 | 28.04K | Dec 30, 2022 |
| iShares Micro Cap ETF | 0.08% | 9,467 | 23.67K | Feb 27, 2023 |
| Fidelity Extended Market Index Fund | 0.05% | 6,011 | 15.03K | Feb 27, 2023 |
| Vanguard Balanced Index Fund | 0.04% | 5,000 | 12.50K | Dec 30, 2022 |